Sedative-Hypnotic Drugs

Correct Answer

C — Non-benzodiazepine gamma-aminobutyric acid type A positive allosteric modulators

Rationale

Zolpidem, zaleplon, and eszopiclone are collectively known as Z-drugs — non-benzodiazepine hypnotics that bind the same benzodiazepine site on the gamma-aminobutyric acid type A receptor. Despite being structurally unrelated to benzodiazepines, they share the same receptor target and are classified as positive allosteric modulators of that receptor. Melatonin receptor agonists, dual orexin receptor antagonists, and barbiturates each represent pharmacologically distinct classes with different receptor targets.

Correct Answer

A — Melatonin receptor types 1 and 2

Rationale

Ramelteon is classified as a selective agonist at melatonin receptor types 1 and 2. These are the two receptor subtypes that mediate the physiological effects of melatonin at the suprachiasmatic nucleus. Ramelteon has no affinity for the gamma-aminobutyric acid type A receptor — distinguishing it from benzodiazepines and Z-drugs. It does not act at orexin receptors or serotonin receptors. Its classification as a melatonin receptor agonist accounts for its unique pharmacological profile among hypnotics.

Correct Answer

B — Aldehyde oxidase

Rationale

Zaleplon is metabolized primarily by aldehyde oxidase, setting it apart from zolpidem and eszopiclone, which are metabolized by cytochrome P450 3A4. This metabolic distinction means zaleplon is substantially less susceptible to the drug interactions that affect other Z-drugs. Cytochrome P450 1A2 is the primary enzyme for ramelteon metabolism. Cytochrome P450 2D6 governs metabolism of many antidepressants and antipsychotics; it plays no significant role in Z-drug metabolism.

Correct Answer

D — Dual orexin receptor antagonists

Rationale

Suvorexant and lemborexant are both classified as dual orexin receptor antagonists — the first pharmacological class developed specifically to promote sleep by blocking orexin-mediated wake drive rather than enhancing inhibitory signaling. The term dual refers to antagonism at both orexin receptor type 1 and orexin receptor type 2. They are not gamma-aminobutyric acid type A modulators, melatonin receptor agonists, or barbiturates — each of those labels belongs to a pharmacologically distinct class with a different primary receptor target.

Correct Answer

A — Eszopiclone

Rationale

Eszopiclone is the only Z-drug with regulatory approval for both sleep-onset and sleep-maintenance insomnia. Its longer half-life of approximately six hours — the longest among the three Z-drugs — supports coverage across the night. Zolpidem immediate-release is approved for sleep-onset insomnia; its extended-release formulation addresses sleep maintenance but is a separate product. Zaleplon, with the shortest half-life of approximately one hour, is approved only for sleep-onset insomnia and middle-of-the-night awakening when sufficient sleep time remains. Triazolam is a benzodiazepine, not a Z-drug.

Correct Answer

C — It is not a controlled substance and has no established abuse or dependence potential

Rationale

Ramelteon is not classified as a controlled substance under the Controlled Substances Act. Because it acts exclusively at melatonin receptors and has no affinity for gamma-aminobutyric acid type A receptors, opioid receptors, or any target associated with abuse or dependence, it carries no established abuse potential. This distinguishes it from benzodiazepines and Z-drugs, which are all Schedule Four controlled substances, and makes ramelteon particularly useful in patients where prescribing a controlled substance is undesirable or contraindicated.

Correct Answer

B — Alpha-1 subunit, which mediates sedation

Rationale

Z-drugs are claimed to preferentially bind gamma-aminobutyric acid type A receptors containing the alpha-1 subunit, which is primarily responsible for the sedative effect. In contrast, alpha-2 and alpha-3 subunits mediate anxiolysis and muscle relaxation respectively — effects less prominent with Z-drugs than with classical benzodiazepines. This selectivity is dose-dependent and partial in practice, meaning the clinical separation from benzodiazepine-like effects is incomplete at higher doses. The beta-2 and gamma-2 subunits serve structural and binding roles but are not the basis of the claimed Z-drug selectivity distinction.

Correct Answer

D — Women have higher and more prolonged zolpidem plasma levels than men at the same dose, causing next-morning driving impairment

Rationale

Driving simulation studies demonstrated that women retained zolpidem plasma concentrations above the impairment threshold the following morning when given the standard 10-milligram dose. This sex-based pharmacokinetic difference — higher and more prolonged plasma levels in women — was the direct basis for the FDA mandating a lower starting dose of 5 milligrams for women. The mechanism relates to differences in clearance rather than absorption rate or production of an active metabolite. This dose revision applies to both immediate-release and extended-release formulations.

Correct Answer

A — Zaleplon has the shortest half-life of the Z-drugs, approximately one hour, allowing near-complete elimination before morning

Rationale

Zaleplon's half-life of approximately one hour is the pharmacokinetic basis for its unique clinical flexibility. If at least four hours of sleep time remain when the patient awakens, a dose of zaleplon will be substantially eliminated by morning, leaving minimal residual sedation. This contrasts with eszopiclone (half-life approximately six hours) and zolpidem immediate-release (half-life 1.5 to 2.5 hours), which carry greater risk of next-morning impairment if taken late at night. Zaleplon's primary metabolism is via aldehyde oxidase, not cytochrome P450 3A4, and it does not produce a self-reversing active metabolite.

Correct Answer

C — Risk of complex sleep behaviors including sleepwalking and sleep-driving; requires immediate discontinuation if such behaviors occur

Rationale

The 2019 FDA boxed warning for all Z-drugs addresses the risk of complex sleep behaviors — activities performed while not fully awake including sleepwalking, sleep-driving, preparing and eating food, and making phone calls, with no memory of the event. These behaviors have resulted in serious injuries and deaths. The warning mandates immediate discontinuation of the medication if any complex sleep behavior occurs, and requires a contraindication for patients who have previously experienced such behaviors with any sedative-hypnotic. Next-morning impairment, dependence, and respiratory concerns are addressed elsewhere in labeling but are not the subject of this specific boxed warning.

Correct Answer

B — Cytochrome P450 1A2; fluvoxamine

Rationale

Ramelteon undergoes extensive first-pass hepatic metabolism primarily via the cytochrome P450 1A2 enzyme. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2 and dramatically increases ramelteon plasma concentrations when co-administered — a combination that is contraindicated. Cytochrome P450 3A4 is the primary metabolic enzyme for most benzodiazepines and Z-drugs such as zolpidem and eszopiclone. Cytochrome P450 2D6 governs metabolism of many antidepressants and antipsychotics. Aldehyde oxidase is the primary enzyme for zaleplon metabolism, not ramelteon.

Correct Answer

A — Ramelteon has no affinity for gamma-aminobutyric acid type A receptors or any target associated with central nervous system depression or reinforcement

Rationale

Ramelteon acts selectively at melatonin receptor types 1 and 2 and has no affinity for gamma-aminobutyric acid type A receptors, opioid receptors, dopamine receptors, or any other target through which classical central nervous system depressants produce reinforcing or dependence-forming effects. Because it does not produce euphoria, sedation of the classical type, or any receptor-mediated effect associated with abuse, it carries no established abuse or dependence potential. Ramelteon does cross the blood-brain barrier to act at suprachiasmatic nucleus melatonin receptors, does produce clinically meaningful central effects on circadian timing, and does not produce rapid tolerance that limits efficacy.

Correct Answer

D — Dual orexin receptor antagonists remove excitatory wake-promoting drive rather than enhancing inhibitory tone

Rationale

Dual orexin receptor antagonists promote sleep by blocking orexin receptors types 1 and 2, thereby removing the tonic excitatory drive that orexinergic neurons provide to wake-promoting centers throughout the brain. This is pharmacologically distinct from benzodiazepines and Z-drugs, which enhance inhibitory gamma-aminobutyric acid signaling — an active suppression of neuronal activity. Dual orexin receptor antagonists do not act on the gamma-aminobutyric acid type A receptor, do not stimulate melatonin release, and do not block histamine receptors. Their mechanistic novelty lies in facilitating sleep by withdrawing wakefulness rather than imposing sedation.

Correct Answer

C — Orexin blockade partially mimics narcolepsy physiology, transiently producing features of the narcoleptic state

Rationale

Narcolepsy type 1 is caused by the selective loss of orexinergic neurons, eliminating orexin signaling entirely. Dual orexin receptor antagonists produce pharmacological blockade of the same orexin system. Incomplete orexin blockade at therapeutic doses can transiently produce features characteristic of narcolepsy, including sleep paralysis, hypnagogic and hypnopompic hallucinations, and cataplexy-like episodes of sudden muscle weakness triggered by strong emotion. These adverse effects are dose-related and mechanistically predictable from the drug class's pharmacology. They do not involve gamma-aminobutyric acid type A receptors, melatonin receptors, or active metabolite accumulation.

Correct Answer

A — Ramelteon acts at melatonin receptors and has no affinity for gamma-aminobutyric acid type A receptors, producing no reinforcing or dependence-forming effects

Rationale

Ramelteon is appropriate for this patient because its mechanism of action — selective agonism at melatonin receptor types 1 and 2 — involves no interaction with gamma-aminobutyric acid type A receptors, opioid receptors, or any target through which sedative-hypnotics produce abuse liability. This receptor profile accounts for its lack of established abuse potential, its absence from controlled substance scheduling, and its explicit recommendation for patients with a history of substance use disorder. Ramelteon is not a partial gamma-aminobutyric acid type A agonist, does not act at orexin receptors, and its suitability in this setting is based on receptor selectivity rather than pharmacokinetic elimination rate.

Correct Answer

B — Zolpidem produced complex behaviors during a state of incomplete arousal by enhancing gamma-aminobutyric acid type A receptor activity in cortical memory-encoding regions

Rationale

This patient experienced a complex sleep behavior — a class of events including sleepwalking, sleep-driving, and other purposeful activities performed in a state of partial arousal with no subsequent memory. Zolpidem and other Z-drugs produce these behaviors through their gamma-aminobutyric acid type A receptor activity, which can suppress memory consolidation and conscious awareness while leaving motor systems partially functional. The 2019 FDA boxed warning for all Z-drugs specifically addresses this risk and requires immediate discontinuation if any complex sleep behavior occurs. Zolpidem does not produce a stimulant metabolite, does not act at melatonin receptors, and the behavior is not a paradoxical excitatory response from interneuron blockade.

Correct Answer

D — It blocks orexin receptor types 1 and 2, removing the excitatory wake-promoting drive that sustains wakefulness

Rationale

Suvorexant promotes sleep by antagonizing both orexin receptor types 1 and 2, thereby blocking the excitatory orexinergic drive that normally maintains wakefulness. This mechanism is mechanistically distinct from zolpidem, which enhances gamma-aminobutyric acid type A receptor inhibitory tone. Because suvorexant removes wake-promoting drive rather than imposing sedation, it preserves normal sleep architecture including slow-wave sleep and rapid eye movement sleep — a property particularly relevant for sleep-maintenance insomnia. Suvorexant does not act on gamma-aminobutyric acid type A receptors, melatonin receptors, or histamine receptors.

Correct Answer

C — Fluvoxamine inhibits cytochrome P450 1A2, the primary enzyme responsible for ramelteon metabolism, causing a dramatic increase in ramelteon plasma levels

Rationale

Ramelteon is metabolized primarily by the cytochrome P450 1A2 enzyme. Fluvoxamine is one of the most potent inhibitors of cytochrome P450 1A2 in clinical use. When these two drugs are combined, fluvoxamine substantially impairs ramelteon clearance, causing ramelteon plasma concentrations to rise to levels far above those achieved with the drug alone — resulting in excessive and prolonged sedation. This combination is specifically contraindicated in ramelteon prescribing information. Fluvoxamine does not act as a melatonin receptor agonist, its relevant interaction with ramelteon is via cytochrome P450 1A2 rather than cytochrome P450 3A4, and the mechanism is metabolic enzyme inhibition rather than protein binding displacement.